Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

DOT1L inhibitor

DRUG CLASS:

DOT1L inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

DOT1L overexpression	Multiple Myeloma	DOT1L overexpression	Multiple Myeloma	DOT1L inhibitor Sensitive: D – Preclinical DOT1L inhibitor Sensitive : D	DOT1L inhibitor Sensitive: D – Preclinical DOT1L inhibitor Sensitive : D
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D
Chr t(11;14)	Leukemia	Chr t(11;14)	Leukemia	DOT1L inhibitor + venetoclax Sensitive: D – Preclinical DOT1L inhibitor + venetoclax Sensitive : D	DOT1L inhibitor + venetoclax Sensitive: D – Preclinical DOT1L inhibitor + venetoclax Sensitive : D
AR-V7 expression	Prostate Cancer	AR-V7 expression	Prostate Cancer	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D
AR-V7 expression	Prostate Cancer	AR-V7 expression	Prostate Cancer	EPZ004777 Sensitive: D – Preclinical EPZ004777 Sensitive : D	EPZ004777 Sensitive: D – Preclinical EPZ004777 Sensitive : D
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	EPZ004777 Sensitive: D – Preclinical EPZ004777 Sensitive : D	EPZ004777 Sensitive: D – Preclinical EPZ004777 Sensitive : D
ALDH1A1 positive	Triple Negative Breast Cancer	ALDH1A1 positive	Triple Negative Breast Cancer	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	VTP-50469 + EPZ-5676 Sensitive: D – Preclinical VTP-50469 + EPZ-5676 Sensitive : D	VTP-50469 + EPZ-5676 Sensitive: D – Preclinical VTP-50469 + EPZ-5676 Sensitive : D